RSLS - ReShape Lifesciences Inc. Stock Price, Fair Value and News

$5.04-0.07 (-1.37%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

RSLS Price Action

Last 7 days

-10.3%

Last 30 days

-23.9%

Last 90 days

-48.2%

Trailing 12 Months

-58.0%

RSLS RSI Chart

RSLS Valuation

Market Cap

148.1M

Price/Earnings (Trailing)

-20.96

Price/Sales (Trailing)

18.1

EV/EBITDA

-21.22

Price/Free Cashflow

-23.9

RSLS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RSLS Fundamentals

RSLS Revenue

Revenue (TTM)

8.2M

Rev. Growth (Yr)

6.36%

Rev. Growth (Qtr)

16.64%

RSLS Earnings

Earnings (TTM)

-7.1M

Earnings Growth (Yr)

55.26%

Earnings Growth (Qtr)

0.88%

RSLS Profitability

Operating Margin

63.95%

EBT Margin

-85.56%

Return on Equity

-475.25%

Return on Assets

-125.86%

Free Cashflow Yield

-4.18%

RSLS Investor Care

Shares Dilution (1Y)

751.20%

Diluted EPS (TTM)

-83.55

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	8.3M	8.0M	8.2M	0
2023	11.1M	10.4M	9.8M	8.7M
2022	12.8M	12.2M	11.3M	11.2M
2021	12.7M	14.6M	14.7M	13.6M
2020	2.3M	3.6M	6.9M	10.3M
2019	9.5M	7.2M	4.5M	3.3M
2018	9.8M	10.6M	10.8M	9.1M
2017	3.8M	5.0M	7.0M	9.9M
2016	4.2M	3.9M	3.6M	3.4M
2015	3.7M	3.8M	3.9M	4.0M
2014	0	0	0	3.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About ReShape Lifesciences Inc.

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

CEO	Mr. Paul F. Hickey
WEBSITE	reshapelifesciences.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	40

ReShape Lifesciences Inc. Frequently Asked Questions

What is the ticker symbol for ReShape Lifesciences Inc.? What does RSLS stand for in stocks?

RSLS is the stock ticker symbol of ReShape Lifesciences Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ReShape Lifesciences Inc. (RSLS)?

As of Wed Nov 20 2024, market cap of ReShape Lifesciences Inc. is 148.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RSLS stock?

You can check RSLS's fair value in chart for subscribers.

Is ReShape Lifesciences Inc. a good stock to buy?

The fair value guage provides a quick view whether RSLS is over valued or under valued. Whether ReShape Lifesciences Inc. is cheap or expensive depends on the assumptions which impact ReShape Lifesciences Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RSLS.

What is ReShape Lifesciences Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, RSLS's PE ratio (Price to Earnings) is -20.96 and Price to Sales (PS) ratio is 18.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RSLS PE ratio will change depending on the future growth rate expectations of investors.